Journal of Neurology

, Volume 257, Issue 5, pp 721–727 | Cite as

Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET

  • Katsutoshi Furukawa
  • Nobuyuki Okamura
  • Manabu Tashiro
  • Masaaki Waragai
  • Shozo Furumoto
  • Ren Iwata
  • Kazuhiko Yanai
  • Yukitsuka Kudo
  • Hiroyuki Arai
Original Communication

Abstract

We recently developed a novel PET tracer, 11C-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole ([11C]BF-227), and had success with in vivo detection of amyloid plaques in Alzheimer’s disease (AD) brains (Kudo et al. in J Nucl Med 8:553–561, 2007). We applied this tracer to subjects with mild cognitive impairment (MCI) and AD in order to elucidate the status of amyloid plaque deposition in MCI and compared the diagnostic performance of BF-227-PET with that of FDG–PET in AD cases. We studied 12 aged normal (AN) subjects, 15 MCIs and 15 ADs with PET using [11C]BF-227. PET images were obtained after administration of BF-227 and the regional standardized uptake value (SUV) and the ratio of regional to cerebellar SUV were calculated as an index of BF-227 binding. AD patients showed increased uptake of [11C]BF-227 in the neocortical areas and striatum as well as decreased glucose metabolism in temporoparietal, posterior cingulate and medial temporal areas. MCI subjects showed a significant increase in BF-227 uptake in the neocortical areas similar to AD, and the most significant difference of BF-227 retention was observed in the parietal lobe if its retentions for MCI were compared to those for AD and AN. On the other hand, glucose hypometabolism in MCI was confined to cingulate and medial temporal cortices. Neocortical BF-227 uptake negatively correlated with glucose metabolism. Receiver operating characteristic (ROC) analysis indicated higher specificity and sensitivity with BF-227-PET than those with FDG–PET for differential diagnosis between AD and normal control. We conclude that [11C]BF-227-PET has a possibility to be a useful technology for early detection of AD pathology and also even in the MCI stage.

Keywords

Alzheimer’s disease Amyloid Senile plaque PET MCI 

References

  1. 1.
    Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS (1993) Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer’s disease. Neurobiol Aging 14:589–596CrossRefPubMedGoogle Scholar
  2. 2.
    Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC (2003) Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60:1374–1377PubMedGoogle Scholar
  3. 3.
    Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B (2005) FDG–PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14–25CrossRefPubMedGoogle Scholar
  4. 4.
    de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B (2001) Fowler et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98:10966–10971CrossRefPubMedGoogle Scholar
  5. 5.
    Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113CrossRefPubMedGoogle Scholar
  6. 6.
    Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A (2008) A PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465CrossRefPubMedGoogle Scholar
  7. 7.
    Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500PubMedGoogle Scholar
  8. 8.
    Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356CrossRefPubMedGoogle Scholar
  9. 9.
    Herholz K, Carter SF, Jones M (2007) PET studies in dementia. Br J Radiol 80:S160–S167CrossRefPubMedGoogle Scholar
  10. 10.
    Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53CrossRefPubMedGoogle Scholar
  11. 11.
    Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63:674–681CrossRefPubMedGoogle Scholar
  12. 12.
    Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606CrossRefPubMedGoogle Scholar
  13. 13.
    Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319CrossRefPubMedGoogle Scholar
  14. 14.
    Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl) -6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med 8:553–561Google Scholar
  15. 15.
    Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62:196–200CrossRefPubMedGoogle Scholar
  16. 16.
    Matsuda H (2007) Role of neuroimaging in Alzheimer’s disease, with emphasis on brain perfusion SPECT. J Nucl Med 48:1289–1300CrossRefPubMedGoogle Scholar
  17. 17.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944PubMedGoogle Scholar
  18. 18.
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94CrossRefPubMedGoogle Scholar
  19. 19.
    Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, Takeda A, Itoh M, Sasaki H (2001) [18F]FDG–PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:447–456CrossRefPubMedGoogle Scholar
  20. 20.
    Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308CrossRefPubMedGoogle Scholar
  21. 21.
    Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194CrossRefPubMedGoogle Scholar
  22. 22.
    Petersen RC, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672CrossRefPubMedGoogle Scholar
  23. 23.
    Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368CrossRefPubMedGoogle Scholar
  24. 24.
    Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Katsutoshi Furukawa
    • 1
  • Nobuyuki Okamura
    • 2
  • Manabu Tashiro
    • 3
  • Masaaki Waragai
    • 1
  • Shozo Furumoto
    • 2
  • Ren Iwata
    • 4
  • Kazuhiko Yanai
    • 2
  • Yukitsuka Kudo
    • 5
  • Hiroyuki Arai
    • 1
  1. 1.Department of Geriatrics and Gerontology, Division of Brain Sciences, Institute of Development, Aging and CancerTohoku UniversitySendaiJapan
  2. 2.Department of PharmacologyTohoku University Graduate School of MedicineSendaiJapan
  3. 3.Division of Cyclotron Nuclear MedicineCyclotron and Radioisotope CenterSendaiJapan
  4. 4.Division of Radiopharmaceutical ChemistryCyclotron and Radioisotope CenterSendaiJapan
  5. 5.Department of NeuroImaging Research, Innovation New Biomedical Engineering CenterTohoku UniversitySendaiJapan

Personalised recommendations